Related Experiment Video

Updated: Aug 4, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.7K

hMSH2 coordinated with the expression of E2F1 promotes platinum response in epithelial ovarian cancer

Xiao-Qian Hu1, Bao-Ying Zhang2, Tian Hua2

  • 1Department of Oncology, Affiliated Xingtai People Hospital of Hebei Medical University, Xingtai, China.

The Journal of International Medical Research
|March 30, 2023
PubMed
Abstract

Insights

The transcription factor E2F1 regulates hMSH2 expression, impacting cisplatin drug resistance in epithelial ovarian cancer (EOC). Lower E2F1 levels correlate with poorer patient survival, suggesting a therapeutic target for EOC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • hMSH2 is crucial for DNA repair and its expression influences cancer treatment outcomes.
  • Understanding the regulation of hMSH2 is key to improving drug susceptibility in epithelial ovarian cancer (EOC).

Purpose of the Study:

  • To identify transcription factors (TFs) regulating hMSH2 expression in EOC.
  • To investigate the role of these TFs in EOC cell response to chemotherapy.

Main Methods:

  • Bioinformatic analysis of TCGA data to predict TFs targeting hMSH2.
  • Experimental validation using RT-qPCR, Western blot, and luciferase assays in ovarian cancer cell lines.
  • Modulation of TF expression (overexpression/knockdown) and assessment of cisplatin sensitivity.

Main Results:

  • The transcription factor E2F1 was identified as a regulator of hMSH2 gene expression.
  • E2F1 expression levels correlated with cisplatin susceptibility in vitro.
  • Kaplan-Meier analysis revealed that low E2F1 expression is associated with worse survival in 77 EOC patients.

Conclusions:

  • This study identifies E2F1-mediated regulation of MSH2 as a novel factor in platinum-based drug resistance in EOC.
  • E2F1 may serve as a predictive biomarker for treatment response and patient survival in EOC.
  • Further research is warranted to confirm these findings and explore therapeutic strategies targeting E2F1.
Keywords:
E2F1Mismatch repairPlatinum resistanceTranscription factorshMSH2

More Related Videos

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K